Glaucoma Market Insights, Epidemiology Facts and Market Report Scope 2032

Posted on
by

Glaucoma Market Insights, Epidemiology Facts and Market Report Scope 2032

DelveInsight’s Glaucoma Market Insights report provides a thorough understanding of current treatment practices, emerging Glaucoma market share of the individual therapies, current and forecasted Glaucoma Market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

 

Glaucoma Overview

Glaucoma is a disease that damages the eye’s optic nerve. It usually happens when fluid builds up in the front part of the eye. That extra fluid increases the pressure in eye, damaging the optic nerve. The condition is a leading cause of blindness for people over 60 years old. But blindness from glaucoma can often be prevented with early treatment.

 

 Some of the key highlights of the Glaucoma market report

  • As per DelveInsight’s analysis, a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries.
  • The total Glaucoma diagnosed prevalent population in the 7MM was estimated as 10,104,188 cases in 2020, which is expected to increase in the forecast period (2021-2030).
  • The Glaucoma Market Size of the 7MM was found to be USD 3,796 million in 2020.
  • The Glaucoma market companies are included like Aerie Pharmaceuticals, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical/Ube Industries, Bausch and Lomb, D.Western Therapeutics Institute (DWTI)/Kowa LTD., Alcon Research, Merck Sharp & Dohme Corp., Novartis/Alcon Research, Allergan, Senju Pharmaceuticals, and many others.
  • The Glaucoma market drugs are included like Rocklatan, Rhopressa, Xelpros (latanoprost ophthalmic emulsion) 0.005%, Eybelis Ophthalmic Solution 0.002% (DE-117, Omidenepag isopropyl), Vyzulta, Tapcom/DE-111 (Tafluprost/timolol maleate), Glanatec, Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%, Zioptan (tafluprost), DuoTrav PQ (travoprost/timolol), Travatan Z (travoprost ophthalmic solution) 0.004%, Lumigan 0.01% (bimatoprost ophthalmic solution), Durysta (Bimatoprost SR), AILAMIDE, Aibeta, and many others.

 

Get Access to a Free Copy of Our Latest Sample Report @ https://www.delveinsight.com/sample-request/glaucoma-market

 

Glaucoma Diagnosis

Although glaucoma is not a curable disease, early diagnosis and adequate treatment are effective in reducing or preventing further optic nerve (ON) damage. The difficulty of distinguishing between eyes without glaucoma and eyes with early or subtle glaucoma is widely acknowledged. Furthermore, there is no unanimous opinion on what constitutes the first signs of damage in glaucoma.

 

Glaucoma Treatment

There is no cure for glaucoma, but early treatment can often stop the damage and protect the vision. Doctors use a few different types of treatment for glaucoma, including medicines (usually eye drops), laser treatment, and surgery.

 

Glaucoma Risk Factors

There are several risk factors like age >60 years, genetic predisposition, certain eye characteristics (such as a pupillary defect, thin cornea, myopia), low educational status, smoking, African descent, and visual problems are associated with this indication and treatment pattern varies accordingly.

 

Glaucoma Types

There are two major types of glaucoma, i.e., Primary open-angle glaucoma (POAG), and Angle-closure /glaucoma closed-angle glaucoma/narrow-angle glaucoma. The “angle” in both cases refers to the drainage angle inside the eye that controls the outflow of the watery fluid (aqueous) which is being produced inside the eye.

 

Glaucoma Market Drivers

  • Rich emerging pipeline
  • Development of treatment methods to tackle the situation of non-adherence
  • Development of advanced antiglaucoma medications
  • Patients-friendly dosage regimes
  • Rise in awareness

 

Glaucoma Market Barriers

  • Approaches to clinical practice
  • Socioeconomic barriers
  • Lack of patient pool due to underdiagnosis

 

Glaucoma Emerging Drugs

  • PDP-716: Sun Pharma Advanced Research Company Limited (SPARC)
  • PRO-122: Laboratorios Sophia S.A de C.V.

 

Glaucoma Market Report Scope

  • The report covers the descriptive overview of Glaucoma, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the Glaucoma epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Glaucoma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Glaucoma market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Glaucoma market

 

Glaucoma Market Companies

  • Aerie Pharmaceuticals
  • Sun Pharma Advanced Research Company Limited
  • Santen Pharmaceutical/Ube Industries, Bausch and Lomb
  • Western Therapeutics Institute (DWTI)/Kowa LTD.
  • Alcon Research
  • Merck Sharp & Dohme Corp
  • Novartis/Alcon Research
  • Allergan
  • Senju Pharmaceuticals
  • And many others

 

Glaucoma Drugs

  • Rocklatan
  • Rhopressa
  • Xelpros (latanoprost ophthalmic emulsion) 0.005%
  • Eybelis Ophthalmic Solution 0.002% (DE-117
  • Omidenepag isopropyl)
  • Vyzulta, Tapcom/DE-111 (Tafluprost/timolol maleate)
  • Glanatec
  • Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%
  • Zioptan (tafluprost)
  • DuoTrav PQ (travoprost/timolol)
  • Travatan Z (travoprost ophthalmic solution) 0.004%
  • Lumigan 0.01% (bimatoprost ophthalmic solution)
  • Durysta (Bimatoprost SR)
  • AILAMIDE
  • Aibeta
  • And many others

 

View Detailed Research Report Here @ https://www.delveinsight.com/sample-request/glaucoma-market

 

Table of content

  1. Key Insights
  2. Report Introduction
  3. Overview at a Glance
  4. Executive Summary of Glaucoma
  5. Disease Background and Overview
  6. Treatment Algorithm for Open-Angle Glaucoma
  7. Treatment for Glaucoma
  8. Epidemiology and Patient Population
  9. Organizations contributing towards Open-Angle Glaucoma (OAG)
  10. Patient Journey
  11. Case Reports
  12. Marketed Products
  13. Emerging Therapies
  14. Glaucoma: Seven Major Market Analysis
  15. KOL Views
  16. Market Drivers
  17. Market Barriers
  18. SWOT Analysis
  19. Unmet Needs
  20. Reimbursement
  21. Appendix
  22. DelveInsight Capabilities
  23. Disclaimer
  24. About DelveInsight

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/